ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

AstraZeneca and Innovent Biologics side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

AstraZenecaInnovent Biologics
studies on the registry4,197218
open to participants now29859
phase 3 studies under way20023
reach primary completion within a year16836
programswith a study of their own in two years119+5 named only40

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseAstraZenecaInnovent Biologics
Phase 1

AstraZeneca: 25 of its 119 programs at phase 1

  1. AZD4954phase 1
  2. AZD1613phase 1
  3. AZD1390phase 1
  4. Actinium Ac 225-DOTA-Anti-STEAP2 Monoclonal Antibody AZD2284phase 1
  5. ALXN2230phase 1

and 20 more — sign in to see them all

21%

Innovent Biologics: 14 of its 40 programs at phase 1

  1. IBI3033phase 1
  2. IBI3032phase 1
  3. IBI3042phase 1
  4. Anti-CEACAM5 Antibody-drug Conjugate IBI3020phase 1
  5. IBI115phase 1

and 9 more — sign in to see them all

35%
Phase 2

AstraZeneca: 47 of its 119 programs at phase 2

  1. AZD9550phase 2
  2. zadavotide guraxetanphase 2
  3. palacaparibphase 2
  4. Berzanoflastphase 2
  5. AZD7798phase 2

and 42 more — sign in to see them all

39%

Innovent Biologics: 10 of its 40 programs at phase 2

  1. IBI3016phase 2
  2. telitaciceptphase 2
  3. IBI355phase 2
  4. IBI3002phase 2
  5. IBI3011phase 2

and 5 more — sign in to see them all

25%
Phase 3

AstraZeneca: 28 of its 119 programs at phase 3

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. tremelimumabphase 3
  4. volrustomigphase 3
  5. Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012Fphase 3

and 23 more — sign in to see them all

24%
38%
Approved, new studies

AstraZeneca: 19 of its 119 programs at approved, new studies

  1. durvalumabapproved, new study
  2. acalabrutinibapproved, new study
  3. trastuzumab deruxtecanapproved, new study
  4. osimertinibapproved, new study
  5. anifrolumabapproved, new study

and 14 more — sign in to see them all

16%

Innovent Biologics: 1 of its 40 programs at approved, new studies

  1. Teprotumumab N01approved, new study
3%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
AstraZeneca60 readouts · 16 phase 3

AstraZeneca, Nov ’26: 4 programs whose next study reaches primary completion

  1. Autologous dnTGF-BRII-armored Anti-STEAP2 CAR T-cells AZD0754phase 2 · Nov 24 · NCT06267729
  2. STEAP2-targeting Radioconjugate AZD2287phase 2 · Nov 24 · NCT06267729
  3. durvalumabapproved, new study · Nov 30 · NCT07081633
  4. tremelimumabphase 3 · Nov 30 · NCT07081633

AstraZeneca, Dec ’26: 7 programs whose next study reaches primary completion, 2 in phase 3

  1. eculizumabapproved, new study · Dec 7 · NCT06724809
  2. AZD3974phase 1 · Dec 8 · NCT07290283
  3. baxdrostatphase 3 · Dec 10 · NCT07222917
  4. dapagliflozinapproved, new study · Dec 10 · NCT07222917
  5. benralizumabapproved, new study · Dec 23 · NCT05692180

and 2 more — sign in to see them all

AstraZeneca, Jan ’27: 13 programs whose next study reaches primary completion, 6 in phase 3

  1. laroprovstatphase 3 · Jan 4 · NCT07000136
  2. anifrolumabapproved, new study · Jan 6 · NCT05925803
  3. monalizumabphase 3 · Jan 8 · NCT05221840
  4. oleclumabphase 3 · Jan 8 · NCT05221840
  5. datopotamab deruxtecanphase 3 · Jan 11 · NCT06417814

and 8 more — sign in to see them all

AstraZeneca, Feb ’27: 7 programs whose next study reaches primary completion, 3 in phase 3

  1. Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012Fphase 3 · Feb 1 · NCT06530849
  2. trastuzumab deruxtecanapproved, new study · Feb 10 · NCT06271837
  3. Berzanoflastphase 2 · Feb 11 · NCT07215702
  4. acalabrutinibapproved, new study · Feb 15 · NCT02972840
  5. zibotentanphase 3 · Feb 18 · NCT06087835

and 2 more — sign in to see them all

AstraZeneca, Mar ’27: 4 programs whose next study reaches primary completion

  1. AZD7760phase 2 · Mar 8 · NCT06749457
  2. AZD4954phase 1 · Mar 17 · NCT07812077
  3. AZD0543phase 1 · Mar 24 · NCT07824622
  4. Anti-Claudin 18.2 Antibody-drug Conjugate AZD4360phase 2 · Mar 31 · NCT06921928

AstraZeneca, Apr ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. AZD1043phase 1 · Apr 9 · NCT07511205
  2. camizestrantphase 3 · Apr 20 · NCT05774951
  3. ombetoxabartphase 2 · Apr 20 · NCT07285213

AstraZeneca, May ’27: 5 programs whose next study reaches primary completion, 2 in phase 3

  1. rilvegostomigphase 3 · May 4 · NCT04379596
  2. Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492phase 2 · May 5 · NCT06916806
  3. AZD1613phase 1 · May 22 · NCT07228364
  4. Budesonideapproved, new study · May 31 · NCT07073950
  5. formoterolapproved, new study · May 31 · NCT07073950

AstraZeneca, Jun ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. tozorakimabphase 3 · Jun 7 · NCT06932263
  2. ravulizumabapproved, new study · Jun 25 · NCT07308574
  3. Anti-GPC3 T Cell-engaging Antibody AZD9793phase 2 · Jun 30 · NCT06795022

AstraZeneca, Jul ’27: 3 programs whose next study reaches primary completion

  1. ALXN1920phase 2 · Jul 2 · NCT07157787
  2. AZD2389phase 2 · Jul 7 · NCT07610837
  3. SC rilvegostomig + rHuphase 1 · Jul 19 · NCT07161414

AstraZeneca, Aug ’27: 4 programs whose next study reaches primary completion

  1. ALXN2230phase 1 · Aug 9 · NCT07352423
  2. AZD0240phase 1 · Aug 30 · NCT06218914
  3. SC durvalumab + rHuphase 1 · Aug 30 · NCT07391670
  4. AZD6793phase 2 · Aug 31 · NCT07082738

AstraZeneca, Sep ’27: 2 programs whose next study reaches primary completion

  1. palacaparibphase 2 · Sep 29 · NCT05123482
  2. puxitatug samrotecanphase 3 · Sep 29 · NCT05123482

AstraZeneca, Oct ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. opemalirsenphase 2 · Oct 4 · NCT06824987
  2. cevolisiranphase 2 · Oct 11 · NCT06744647
  3. tarperprumigphase 2 · Oct 11 · NCT07160608
  4. torvutatug samrotecanphase 3 · Oct 15 · NCT07402915
  5. sodium zirconium cyclosilicateapproved, new study · Oct 30 · NCT07944378
Innovent Biologics18 readouts · 4 phase 3

Innovent Biologics, Nov ’26: 1 program whose next study reaches primary completion

  1. Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363phase 3 · Nov 30 · NCT07122687

Innovent Biologics, Dec ’26: 6 programs whose next study reaches primary completion, 3 in phase 3

  1. arcotatug tavatecanphase 3 · Dec 30 · NCT06238843
  2. GPRC5D/BCMA/CD3-targeting T-cell Engager IBI3003phase 3 · Dec 31 · NCT07764861
  3. IBI302phase 3 · Dec 31 · NCT06908876
  4. IBI3026early phase 1 · Dec 31 · NCT07327632
  5. IBI311phase 3 · Dec 31 · NCT07113262

and 1 more — sign in to see them all

Innovent Biologics, Jan ’27: 3 programs whose next study reaches primary completion

  1. IBI3016phase 2 · Jan 30 · NCT07838220
  2. IBI3034phase 1 · Jan 31 · NCT07886476
  3. telitaciceptphase 2 · Jan 31 · NCT07886476

Innovent Biologics, Feb ’27: 1 program whose next study reaches primary completion

  1. IBI3033phase 1 · Feb 10 · NCT07549984

Innovent Biologics, Mar ’27: 2 programs whose next study reaches primary completion

  1. IBI3042phase 1 · Mar 2 · NCT07842393
  2. IBI3002phase 2 · Mar 23 · NCT07399067

Innovent Biologics, Apr ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. tigulixostatphase 3 · Apr 30 · NCT07414394

Innovent Biologics, May ’27: 1 program whose next study reaches primary completion

  1. IBI3011phase 2 · May 11 · NCT07842497

Innovent Biologics, Jun ’27: 2 programs whose next study reaches primary completion

  1. IBI3031phase 1 · Jun 15 · NCT07622368
  2. IBI3028phase 1 · Jun 30 · NCT07589205

Innovent Biologics, Jul ’27: 1 program whose next study reaches primary completion

  1. IBI3035phase 1 · Jul 30 · NCT07591519
···
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

AstraZeneca

New programs 2

Reached a new phase 1

Study stopped 0

None

Primary completion later 23

Innovent Biologics

New programs 4

  • IBI3043phase 1 · first study · Oct 22
  • IBI3034phase 1 · first study · Oct 8 · Glomerulonephritis, IGA
  • telitaciceptphase 2 · first study · Sep 13 · Lupus Erythematosus, Systemic
  • IBI3046phase 1 · first study · Sep 3 · Obesity

Reached a new phase 2

  • IBI3011phase 2 · Sep 14 · Gout
  • IBI355phase 2 · Sep 13 · Sjogren's Syndrome

Study stopped 1

  • IBI356phase 2 · terminated Oct 27 · none of its studies left running“Sponsor Decision” · NCT07330934

Primary completion later 1

Where they overlap

Conditions where at least two of them have programs: 27 in all, the first 12 here. A program counts in each condition its studies name most.

ConditionAstraZenecaInnovent Biologics
Carcinoma, Non-Small-Cell Lungboth · compare here

AstraZeneca in Carcinoma, Non-Small-Cell Lung: 16 programs

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. tremelimumabphase 3
  4. volrustomigphase 3
  5. ceralasertibphase 3

and 11 more — sign in to see them all

Their studies: AstraZeneca’s studies of Carcinoma, Non-Small-Cell Lung in search

Innovent Biologics in Carcinoma, Non-Small-Cell Lung: 5 programs

  1. Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363phase 3
  2. sintilimabphase 3
  3. gimeracilphase 2
  4. Oxonic Acidphase 2
  5. Tegafurphase 2

Their studies: Innovent Biologics’ studies of Carcinoma, Non-Small-Cell Lung in search

Stomach Neoplasmsboth · compare here

Innovent Biologics in Stomach Neoplasms: 4 programs

  1. sintilimabphase 3
  2. gimeracilphase 2
  3. Oxonic Acidphase 2
  4. Tegafurphase 2

Their studies: Innovent Biologics’ studies of Stomach Neoplasms in search

Asthmaboth · compare here

AstraZeneca in Asthma: 10 programs

  1. tozorakimabphase 3
  2. BFF MDIphase 3
  3. GP MDIphase 3
  4. londamocitinibphase 2
  5. sunakimentphase 2

and 5 more — sign in to see them all

Their studies: AstraZeneca’s studies of Asthma in search

Innovent Biologics in Asthma: 1 program

  1. IBI3002phase 2

Their studies: Innovent Biologics’ studies of Asthma in search

Breast Neoplasmsboth · compare here

AstraZeneca in Breast Neoplasms: 10 programs

  1. datopotamab deruxtecanphase 3
  2. saruparibphase 3
  3. capivasertibphase 3
  4. camizestrantphase 3
  5. puxitatug samrotecanphase 3

and 5 more — sign in to see them all

Their studies: AstraZeneca’s studies of Breast Neoplasms in search

Innovent Biologics in Breast Neoplasms: 1 program

  1. Anti-HER2 Antibody-drug Conjugate IBI354phase 3

Their studies: Innovent Biologics’ studies of Breast Neoplasms in search

Renal Insufficiencyboth · compare here

AstraZeneca in Renal Insufficiency: 8 programs

  1. elecoglipronphase 3
  2. lenbelintidephase 3
  3. zibotentanphase 3
  4. balcinrenonephase 3
  5. opemalirsenphase 2

and 3 more — sign in to see them all

Their studies: AstraZeneca’s studies of Renal Insufficiency in search

Innovent Biologics in Renal Insufficiency: 3 programs

  1. gimeracilphase 2
  2. Oxonic Acidphase 2
  3. Tegafurphase 2

Their studies: Innovent Biologics’ studies of Renal Insufficiency in search

Carcinoma, Hepatocellularboth · compare here

AstraZeneca in Carcinoma, Hepatocellular: 6 programs

  1. rilvegostomigphase 3
  2. tremelimumabphase 3
  3. Leucovorinphase 2
  4. Anti-GPC3 T Cell-engaging Antibody AZD9793phase 2
  5. Ramucirumabphase 2

and 1 more — sign in to see them all

Their studies: AstraZeneca’s studies of Carcinoma, Hepatocellular in search

Innovent Biologics in Carcinoma, Hepatocellular: 2 programs

  1. sintilimabphase 3
  2. Anti-CTLA-4 Monoclonal Antibody IBI310phase 3

Their studies: Innovent Biologics’ studies of Carcinoma, Hepatocellular in search

Obesityboth · compare here

AstraZeneca in Obesity: 4 programs

  1. elecoglipronphase 3
  2. lenbelintidephase 3
  3. AZD9550phase 2
  4. AZD1043phase 1

Their studies: AstraZeneca’s studies of Obesity in search

Innovent Biologics in Obesity: 4 programs

  1. mazdutidephase 3
  2. IBI3032phase 1
  3. IBI3042phase 1
  4. IBI3046phase 1

Their studies: Innovent Biologics’ studies of Obesity in search

Colorectal Neoplasmsboth · compare here

AstraZeneca in Colorectal Neoplasms: 1 program

  1. Leucovorinphase 2

Their studies: AstraZeneca’s studies of Colorectal Neoplasms in search

Diabetes Mellitus, Type 2both · compare here

AstraZeneca in Diabetes Mellitus, Type 2: 5 programs

  1. elecoglipronphase 3
  2. lenbelintidephase 3
  3. AZD6793phase 2
  4. Elecoglipron Test formulation 1 Dose Aphase 1
  5. dapagliflozinapproved, new study

Their studies: AstraZeneca’s studies of Diabetes Mellitus, Type 2 in search

Innovent Biologics in Diabetes Mellitus, Type 2: 1 program

  1. mazdutidephase 3

Their studies: Innovent Biologics’ studies of Diabetes Mellitus, Type 2 in search

Lymphoma, Follicularboth · compare here

AstraZeneca in Lymphoma, Follicular: 5 programs

  1. surovatamigphase 3
  2. camizestrantphase 3
  3. lenbelintidephase 3
  4. AZD9550phase 2
  5. AZD2389phase 2

Their studies: AstraZeneca’s studies of Lymphoma, Follicular in search

Innovent Biologics in Lymphoma, Follicular: 1 program

  1. telitaciceptphase 2

Their studies: Innovent Biologics’ studies of Lymphoma, Follicular in search

Pancreatic Neoplasmsboth · compare here

AstraZeneca in Pancreatic Neoplasms: 2 programs

  1. sonesitatug vedotinphase 3
  2. Leucovorinphase 2

Their studies: AstraZeneca’s studies of Pancreatic Neoplasms in search

Innovent Biologics in Pancreatic Neoplasms: 4 programs

  1. arcotatug tavatecanphase 3
  2. gimeracilphase 2
  3. Oxonic Acidphase 2
  4. Tegafurphase 2

Their studies: Innovent Biologics’ studies of Pancreatic Neoplasms in search

Dermatitis, Atopicboth · compare here

AstraZeneca in Dermatitis, Atopic: 1 program

  1. tezepelumabapproved, new study

Their studies: AstraZeneca’s studies of Dermatitis, Atopic in search

Innovent Biologics in Dermatitis, Atopic: 4 programs

  1. IBI3027phase 3
  2. IBI3002phase 2
  3. IBI356phase 2
  4. IBI3033phase 1

Their studies: Innovent Biologics’ studies of Dermatitis, Atopic in search

Show all 27

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: AstraZeneca 68 of 119 · Innovent Biologics 16 of 40 programs (45 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (AstraZeneca: 5).